James Mackin Sells 20,962 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 20,962 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $37.59, for a total transaction of $787,961.58. Following the completion of the sale, the chief executive officer directly owned 780,031 shares in the company, valued at approximately $29,321,365.29. This trade represents a 2.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Artivion Stock Up 6.6%

Artivion stock opened at $38.14 on Friday. The firm has a 50 day simple moving average of $42.09 and a 200 day simple moving average of $43.05. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 190.71 and a beta of 1.59.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.Artivion’s revenue was up 19.2% compared to the same quarter last year. On average, analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Ratings Changes

AORT has been the topic of a number of recent analyst reports. Citizens Jmp increased their price target on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Canaccord Genuity Group lowered their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Needham & Company LLC restated a “buy” rating and set a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Oppenheimer reissued an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.97.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AORT. Aster Capital Management DIFC Ltd lifted its stake in Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Artivion in the 3rd quarter worth approximately $27,000. Larson Financial Group LLC lifted its position in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the last quarter. USA Financial Formulas boosted its stake in Artivion by 163.5% in the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after buying an additional 703 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 results topped expectations — revenue grew ~19% year‑over‑year and EPS beat consensus, supporting revenue momentum and margin recovery; this helps justify the current rally. Earnings & Company Page
• Positive Sentiment: Short interest fell ~15.4% in February to ~1.39M shares (~3.2% of float); lower short exposure reduces one source of downside selling and can make up‑moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Institutional investors have increased or initiated positions in recent quarters (multiple funds cited), indicating professional conviction that could support longer‑term demand. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed — consensus is a “Moderate Buy” with an average target near $49, but some shops have trimmed targets or moved to Hold, reflecting divergent views on near‑term upside. Analyst Notes
• Negative Sentiment: Large, broad insider selling across Feb. 23–24 (CEO James P. Mackin, EVP Lance Berry, SVPs and CAO made sizable open‑market disposals). While filings suggest open‑market liquidity/scheduled sales rather than insider panic, the scale and breadth can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.